Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, making up more than 80% of cases. Pancreatic cancer develops in the pancreas but cancer cells can spread aggressively to distant sites in the body – a process called metastasis – meaning patients can get metastatic – or secondary – tumours. Cytotoxic chemotherapy is the standard care treatment for patients in advanced stages of the disease. The understanding of how these metastatic tumours react to chemotherapy and its role in metastatic disease progression post-treatment is currently poor. Read more . . .
A new Liverpool led study, published in Gut, has identified how immune cells in the body can promote the regrowth of cancer cells after chemotherapy withdrawal. These findings will help improve the effectiveness of chemotherapy in patients with certain cancers.